{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-141488","form_type":"8-K","ticker":"DBVT","cik":"0001613780","company_name":"DBV Technologies S.A.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.669137+00:00","generated_at":"2026-06-15T04:12:02.098635+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"DBV Technologies announces NEJM publication of Phase 3 EPITOPE trial for Viaskin Peanut in toddlers","bullets":["NEJM published Phase 3 EPITOPE data showing Viaskin Peanut statistically superior to placebo in desensitizing toddlers (1-3 years) to peanut.","Treatment responder rates: 67.0% for Viaskin Peanut vs 33.5% for placebo after 12 months.","No FDA-approved treatment options exist for peanut-allergic children under 4 years; DBV is advancing regulatory efforts for this age group.","Viaskin Peanut was well-tolerated with low rates of treatment-related anaphylaxis and epinephrine use; local application site reactions decreased over time.","Editorial in NEJM called the data 'very good news' for toddlers with peanut allergy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-141488","json":"https://secwatch.observer/filing/0001193125-23-141488.json","markdown":"https://secwatch.observer/filing/0001193125-23-141488.md","text":"https://secwatch.observer/filing/0001193125-23-141488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613780/000119312523141488/0001193125-23-141488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613780/000119312523141488/d237467d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:12:02.098635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}